![]() | Alberto ZanchettiShow email addressIstituto Auxologico Italiano, IRCCS, and Università degli Studi of Milan, Italy. | Centro di Fisiologia Clinica e Ipertensione, Università degli Studi di Milano, Milan, Italy ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Alberto Zanchetti:Expert Impact
Concepts for whichAlberto Zanchettihas direct influence:Blood pressure,Hypertensive patients,Essential hypertension,Ventricular hypertrophy,Metabolic syndrome,Antihypertensive treatment,Renin release,Cardiovascular risk.
Alberto Zanchetti:KOL impact
Concepts related to the work of other authors for whichfor which Alberto Zanchetti has influence:Blood pressure,Hypertensive patients,Cardiovascular disease,Metabolic syndrome,Heart rate,Arterial stiffness,Resistant hypertension.
KOL Resume for Alberto Zanchetti
Year | |
---|---|
2019 | Istituto Auxologico Italiano, IRCCS, and Università degli Studi of Milan, Italy. Centro di Fisiologia Clinica e Ipertensione, Università degli Studi di Milano, Milan, Italy |
2018 | The Istituto Auxologico Italiano, Milan, Italy Istituto Auxologico Italiano IRCCS, Scientific Direction. |
2017 | Istituto Auxologico Italiano, Centro Interuniversitario di Fisiologia Clinica e Ipertensione, University of Milan, Italia. |
2016 | Centro di Fisiologia Clinica e Ipertensione, Università degli Studi di Milano, Italy University of Alabama at Birmingham, Birmingham, AL, USA Istituto Auxologico Italiano, Milan, ITALY |
2015 | Istituto Auxologico Italiano IRCCS and Centro Interuniversitario di Fisiologia Clinica e Ipertensione, University of Milan , Via L. Ariosto, 13, I-20145 Milano , Italy +39 02 619112237 ; +39 02 619112901 ; University of Milan and Instituto Auxologico Italiano, Milan, Italy |
2014 | Centro Fisiologia Clinica e Ipertensione, University of Milan, and Istituto Auxologico Italiano, Milan, Italy Author affiliations are listed on the Journal website, http://links.lww.com/HJH/A366 Instituto Auxológico Italiano, Milão, Itália |
2013 | University of Milan, Milan, Italy Italia |
2012 | Centro di Fisiologia Clinica e Ipertensione Università di Milano and Istituto Auxologico Italiano, Milan, Italy |
2011 | From the Istituto Auxologico Italiano and the University of Milan, Milan, Italy. Centro Interuniversitario di Fisiologia Clinica e Ipertensione, Università di Milano and Istituto Auxologico Italiano, Milan, Italy |
2010 | Centre of Clinical Physiology and Hypertension, University of Milan, Milan Centro Interuniversitario de Fisiología Clínica e Hipertensión, Universidad de Milán e Instituto Auxologico Italiano, Milán, Italia |
2009 | From Centro Interuniversitario di Fisiologia Clinica e Ipertensione, Università di Milano, Milan, Italy (A.Z.); Istituto Auxologico Italiano, Milan, Italy (A.Z., C.C., G.P.); Institute for Medical Statistics and Epidemiology, Technische Universität München, Munich, Germany (M.H., R.H.); Division of Vascular Ultrasound Research, Wake Forest University School of Medicine, Winston-Salem, NC (G.B., R.T.); and Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie,... Centro Interuniversitario di Fisiologia Clinica e Ipertensione, University of Milano, Milano, Italy |
Concept | World rank |
---|---|
arb 1 | #1 |
chlorthalidone decrease | #1 |
reliability cbmmax | #1 |
hyperuricemia hypokalemia | #1 |
sinoaortic reflexes | #1 |
rvwt31 | #1 |
female heart hypertension | #1 |
chlorthalidone verapamil | #1 |
rate thickness | #1 |
orally administered verapamil | #1 |
microalbuminuria study population | #1 |
goals trials | #1 |
atenolol regimens baseline | #1 |
subgroup treatment interaction | #1 |
impact lvh | #1 |
75 years association | #1 |
candesartan cardiovascular | #1 |
cardiovascular events verapamil | #1 |
dippers monitoring sessions | #1 |
1 lifestyle | #1 |
hypertension molecular determinants | #1 |
treated chinese patients | #1 |
80 mmhg evidence | #1 |
imt hypertensive patients | #1 |
obstculos | #1 |
chapter release | #1 |
classes head | #1 |
24month data | #1 |
vhas antihypertensive treatment | #1 |
kidney dysfunction p0001 | #1 |
noadd | #1 |
hypotensive renin | #1 |
egfrckdepi female follow | #1 |
uae cardiovascular risk | #1 |
endpoints total cholesterol | #1 |
125 110 | #1 |
latin medicine | #1 |
ventricular mass normotensives | #1 |
women tchd | #1 |
abpm recording | #1 |
ultrasound examination heart | #1 |
intense lowering | #1 |
abpm essential hypertension | #1 |
treated patients clinic | #1 |
lvmi ventricular losartan | #1 |
ambulatory carotid arteries | #1 |
8 weeks manidipine | #1 |
effects myocardial fibrosis | #1 |
afferent posture receptors | #1 |
a24 slope | #1 |
Sign-in to see all concepts, it's free! | |
Prominent publications by Alberto Zanchetti
BACKGROUND: Daily aspirin reduces the long-term risk of death due to cancer. However, the short-term effect is less certain, especially in women, effects on cancer incidence are largely unknown, and the time course of risk and benefit in primary prevention is unclear. We studied cancer deaths in all trials of daily aspirin versus control and the time course of effects of low-dose aspirin on cancer incidence and other outcomes in trials in primary prevention.
METHODS: We studied ...
Known for Cancer Incidence | Daily Aspirin | Vascular Death | Primary Prevention | Reduced Risk |
OBJECTIVE: To compare the effects of the angiotensin II antagonist, losartan, with those of atenolol on left ventricular hypertrophy (LVH), blood pressure and neurohormone concentrations in hypertensive patients with LVH.
DESIGN: A multinational, randomized, double-blind trial.
SETTING: Hospital.
PATIENTS: Hypertensive patients with an echocardiographically documented left ventricular mass index (LVMI) 120 g/m(2) (men) or 105 g/m(2) (women).
INTERVENTIONS: Patients allocated randomly to ...
Known for Losartan Atenolol | Ventricular Mass | Blood Pressure | Essential Hypertension | 36 Weeks |
BACKGROUND: Despite treatment, there is often a higher incidence of cardiovascular complications in patients with hypertension than in normotensive individuals. Inadequate reduction of their blood pressure is a likely cause, but the optimum target blood pressure is not known. The impact of acetylsalicylic acid (aspirin) has never been investigated in patients with hypertension. We aimed to assess the optimum target diastolic blood pressure and the potential benefit of a low dose of ...
Known for Acetylsalicylic Acid | Patients Hypertension | Pressure Lowering | Major Cardiovascular Events | Aspirin Blood |
BACKGROUND: In cross-sectional studies, ambulatory blood pressure (ABP) correlates more closely than clinic BP with the organ damage of hypertension. Whether ABP predicts development or regression of organ damage over time better than clinic BP, however, is unknown.
METHODS AND RESULTS: In 206 essential hypertensive subjects with left ventricular hypertrophy (LVH), we measured clinic supine BP, 24-hour ABP, and left ventricular mass index (LVMI, echocardiography) before and after 12 ...
Known for Clinic Blood | Ambulatory Monitoring | Ventricular Hypertrophy | Sample Study | Lvh Regression |
Serum uric acid for short-term prediction of cardiovascular disease incidence in the Gubbio population Study
[ PUBLICATION ]
OBJECTIVE: The Gubbio Study is an Italian population study measuring risk factors for and incidence of major cardiovascular diseases. This analysis investigates the association of serum uric acid with the incidence of coronary and cardiovascular events.
METHODS: A population sample of 2469 men and women aged 35-74 years, free from major cardiovascular diseases and in whom serum uric acid was measured in 1983 along with other standard risk factors, were followed up for 6 years and the ...
Known for Serum Uric Acid | Gubbio Population Study | Cvd Events | Cardiovascular Disease | Chd Incidence |
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
[ PUBLICATION ]
BACKGROUND: Isolated systolic hypertension occurs in about 15% of people aged 60 years or older. In 1989, the European Working Party on High Blood Pressure in the Elderly investigated whether active treatment could reduce cardiovascular complications of isolated systolic hypertension. Fatal and non-fatal stroke combined was the primary endpoint.
METHODS: All patients (> 60 years) were initially started on masked placebo. At three run-in visits 1 month apart, their average sitting ...
Known for Active Treatment | Isolated Systolic Hypertension | Cardiovascular Complications | Patients 60 Years | Mm Hg |
The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients
[ PUBLICATION ]
OBJECTIVE: To compare the incidence of stroke and other cardiovascular events in hypertensive patients receiving a low-dose diuretic and low-dose calcium antagonist combination with those receiving low-dose diuretic monotherapy, and assess the effects of a small blood pressure difference at achieved levels lower than those achieved in previous placebo-controlled trials.
METHODS: The Felodipine Event Reduction (FEVER) trial was an investigator-designed, prospective, multicentre, ...
Known for Hypertensive Patients | Cardiovascular Events | Controlled Trial | Felodipine Event Reduction | Low Dose |
BACKGROUND: It is unclear whether the carotid intima-media thickness can be influenced by antihypertensive treatment and whether some antihypertensive agents, such as calcium antagonists, may have a greater effect on this parameter than others, such as diuretics. The present paper reports the principal results of the ultrasound substudy of the randomized, prospective, controlled, Verapamil in Hypertension and Atherosclerosis Study (VHAS).
DESIGN AND METHODS: In 498 hypertensive patients ...
Known for Carotid Plaques | Mm Patients | Atherosclerosis Study | Media Thickness | Antihypertensive Treatment |
Risk factors associated with alterations in carotid intima—media thickness in hypertension
[ PUBLICATION ]
BACKGROUND: The possibility that calcium antagonists exert an anti-atherosclerotic action at least partly independently of the blood-pressure-lowering effect is supported by results of a large number of experimental studies and can now be investigated by quantitative B-mode ultrasound imagining of the carotid artery walls.
DESIGN: The European Lacidipine Study on Atherosclerosis (ELSA) is a prospective, randomized, double-blind, multinational trial comparing effects of 4-year treatment ...
Known for Media Thickness | Carotid Intima | Baseline Data | Systolic Blood Pressure | Calcium Antagonists |
Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome
[ PUBLICATION ]
BACKGROUND: The cardiac effects of hypertension include a variety of structural changes such as increases in left ventricular mass (LVM) and left atrium (LA) size. Although data on hypertension-induced left ventricular changes are extensive, relatively little information is available on LA size from large-scale studies.
OBJECTIVE: We sought to assess the prevalence of LA enlargement in a large selected hypertensive population and to determine the relations of LA size to several biologic ...
Known for Ventricular Geometry | Metabolic Syndrome | Atrial Enlargement | Women Lvh | Essential Hypertension |
This double-blind, multicenter trial compared antihypertensive efficacy, tolerability, and impact on quality of life of manidipine and amlodipine in patients with mild-to-moderate essential hypertension. Patients were randomly assigned to 48 weeks of once-daily manidipine, 10-20 mg, or amlodipine, 5-10 mg. Patients who did not respond to treatment after 12 weeks were also given enalapril, 10-20 mg, for the study's duration. The main efficacy end point was equivalence in sitting systolic ...
Known for Manidipine Amlodipine | Essential Hypertension | Quality Life | 8 Weeks | Antihypertensive Efficacy |
BACKGROUND AND OBJECTIVES: In 68 randomized controlled trials (RCTs), blood pressure (BP) lowering was obtained by using drugs of different classes. We have investigated whether BP lowering by any of the major drug classes is effective in reducing the cardiovascular outcomes.
METHODS: A total of 55 RCTs (19,5 267 individuals) were suitable for drug-class meta-analyses. Risk ratios and their 95% confidence intervals of seven fatal and nonfatal outcomes were estimated by a random-effects ...
Known for Outcome Incidence | Blood Pressure | Major Cardiovascular Events | Antihypertensive Agents | Heart Failure |